Filtros de búsqueda

Lista de obras de

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

scientific article published on 31 October 2019

A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2004

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

artículo científico publicado en 2016

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

artículo científico publicado en 2010

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

artículo científico publicado en 2016

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

artículo científico publicado en 2005

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

artículo científico publicado en 2010

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

artículo científico publicado en 2005

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

artículo científico publicado en 2014

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells ⬇️

artículo científico publicado el 31 de marzo de 2011

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.

artículo científico publicado en 2017

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

artículo científico publicado el 18 de agosto de 2011

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2019

A phase 2 study of bortezomib in relapsed, refractory myeloma

artículo científico publicado en 2003

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

artículo científico publicado en 2014

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2011

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

artículo científico publicado en 2010

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

artículo científico publicado en 2017

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

artículo científico publicado en 2008

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

artículo científico publicado en 2012

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

artículo científico publicado en 2012

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

artículo científico publicado en 2016

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

artículo científico publicado en 2018

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

artículo científico publicado en 2006

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

artículo científico publicado en 2010

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

artículo científico publicado en 2008

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

artículo científico publicado en 2017

An update of novel therapeutic approaches for multiple myeloma

artículo científico publicado en 2004

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

artículo científico publicado en 2008

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration

artículo científico publicado en 2013

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

artículo científico publicado en 2008

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

artículo científico publicado en 2007

Antimyeloma activity of heat shock protein-90 inhibition.

artículo científico publicado en 2005

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

artículo científico publicado en 2009

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

artículo científico publicado en 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

artículo científico publicado en 2002

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

scientific article published on 13 December 2018

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

artículo científico publicado en 2018

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

artículo científico publicado en 2005

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

artículo científico publicado en 2011

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

artículo científico publicado en 2006

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Best treatment strategies in high-risk multiple myeloma: navigating a gray area

artículo científico publicado en 2014

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

artículo científico publicado en 2006

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

artículo científico publicado en 2009

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines

artículo científico publicado en 2003

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

artículo científico publicado en 2002

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

artículo científico publicado en 2014

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

artículo científico publicado en 2012

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers ⬇️

artículo científico publicado el 1 de septiembre de 2003

Bortezomib and dexamethasone induction for multiple myeloma ⬇️

artículo científico publicado el 1 de enero de 2011

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

artículo científico publicado en 2014

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

artículo científico publicado en 2006

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

artículo científico publicado en 2005

Bortezomib in the front-line treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib in the management of multiple myeloma ⬇️

artículo científico publicado el 8 de septiembre de 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

artículo científico publicado en 2009

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

artículo científico publicado en 2008

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2005

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

artículo científico publicado en 2010

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib-induced tumor lysis syndrome in multiple myeloma

artículo científico publicado en 2006

Bortezomib: a novel therapy approved for multiple myeloma

artículo científico publicado en 2003

Bortezomib: proteasome inhibition as an effective anticancer therapy

artículo científico publicado en 2006

Bortezomib: proteasome inhibition as an effective anticancer therapy

scientific article published on 01 April 2005

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

artículo científico publicado en 2012

CD38 antibodies in multiple myeloma: back to the future

artículo científico publicado en 2017

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

scientific article published on 15 April 2015

Can thalidomide improve outcome in patients with multiple myeloma?

scientific article published on 01 November 2006

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

artículo científico publicado en 2011

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review

artículo científico publicado en 2016

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

artículo científico publicado en 2004

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

artículo científico publicado en 2008

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating

artículo científico publicado en 2011

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

artículo científico publicado en 2010

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation

scientific article published on 29 April 2020

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

artículo científico publicado en 2009

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

scientific article published on 23 May 2016

Clinical translation in multiple myeloma: from bench to bedside

artículo científico

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

artículo científico publicado en 2008

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

artículo científico publicado en 2015

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2009

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

artículo científico publicado en 2007

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

artículo científico publicado en 2004

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

artículo científico publicado en 2012

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

artículo científico publicado en 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor

scientific article published on 07 March 2020

Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolesce

artículo científico publicado en 2017

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

artículo científico publicado en 2011

Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes

artículo científico

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

scientific article published on 01 May 2019

Current strategies for treatment of relapsed/refractory multiple myeloma

artículo científico publicado en 2014

Current therapeutic uses of lenalidomide in multiple myeloma

artículo científico publicado en 2006

Current treatment landscape for relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Current use of monoclonal antibodies in the treatment of multiple myeloma.

artículo científico publicado en 2018

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

artículo científico publicado en 2002

Daratumumab granted breakthrough drug status

artículo científico publicado en 2014

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

artículo científico publicado en 2020

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

scientific article published on 23 April 2020

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma

artículo científico publicado en 2016

Deacetylase inhibitors: an advance in myeloma therapy?

artículo científico publicado en 2017

Deciphering the chronology of copy number alterations in Multiple Myeloma

artículo científico publicado en 2019

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research

artículo científico publicado en 2016

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program

artículo científico publicado en 2016

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation

artículo científico publicado en 2012

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure

article

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial

artículo científico publicado en 2010

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

artículo científico publicado en 2015

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement

scientific article published on 07 December 2019

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

artículo científico publicado en 2007

Differential and limited expression of mutant alleles in multiple myeloma

artículo científico publicado en 2014

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

artículo científico publicado en 2016

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

artículo científico publicado en 2007

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

artículo científico

Drug safety evaluation of defibrotide

artículo científico

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma

artículo científico publicado en 2012

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation

scientific article published on 03 August 2018

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

artículo científico publicado en 2014

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

artículo científico publicado en 2015

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells ⬇️

artículo científico publicado el 1 de octubre de 2003

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

artículo científico publicado en 2010

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

artículo científico publicado en 2015

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

artículo científico publicado en 2018

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2018

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial

artículo científico publicado en 2018

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma

artículo científico

Emerging drugs in multiple myeloma

artículo científico publicado en 2007

Emerging therapies for multiple myeloma

artículo científico publicado en 2009

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

artículo científico publicado en 2009

Emerging trends in the clinical use of bortezomib in multiple myeloma

artículo científico publicado en 2005

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

artículo científico publicado el 13 de diciembre de 2012

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

artículo científico publicado en 2019

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

artículo científico publicado en 2015

Evolving strategies in the initial treatment of multiple myeloma

artículo científico

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes ⬇️

artículo científico publicado el 24 de abril de 2003

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

artículo científico publicado en 2009

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

artículo científico publicado en 2006

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

artículo científico publicado en 2006

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

artículo científico publicado en 2005

Fatty acid synthase is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2008

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

article

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome

scientific article published on 16 May 2018

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function

artículo científico publicado en 2004

From the bench to the bedside: emerging new treatments in multiple myeloma

artículo científico publicado en 2007

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

artículo científico publicado en 2009

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

artículo científico publicado en 2011

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2003

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

artículo científico publicado en 2006

Genetic variation associated with bortezomib-induced peripheral neuropathy ⬇️

artículo científico publicado el 1 de marzo de 2011

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

artículo científico publicado en 2018

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

artículo científico publicado en 2015

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

artículo científico publicado en 2012

Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.

artículo científico publicado en 2012

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article published on 09 April 2020

Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma

scientific article published on 29 May 2018

Hematology: Thalidomide maintenance in multiple myeloma

artículo científico publicado en 2009

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide

artículo científico publicado en 2007

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

artículo científico publicado en 2009

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

artículo científico publicado en 2014

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

artículo científico publicado en 2007

Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy ⬇️

artículo científico publicado el 17 de junio de 2013

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

artículo científico publicado en 2018

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

artículo científico publicado en 2005

How I treat multiple myeloma in younger patients

artículo científico publicado en 2009

How I treat plasma cell leukemia

artículo científico publicado en 2012

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

artículo científico publicado en 2018

Identification and validation of novel therapeutic targets for multiple myeloma

artículo científico publicado en 2005

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.

artículo científico publicado en 2013

IgM myeloma: A multicenter retrospective study of 134 patients

artículo científico publicado en 2017

Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone ⬇️

artículo científico publicado el 11 de junio de 2012

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

artículo científico publicado en 2004

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

artículo científico publicado en 2002

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

artículo científico publicado en 2003

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

artículo científico publicado en 2010

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

artículo científico publicado en 2018

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.

artículo científico publicado en 2017

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

artículo científico publicado en 2017

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells ⬇️

artículo científico publicado el 12 de abril de 2013

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

artículo científico publicado en 2011

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

artículo científico publicado en 2009

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes With Defibrotide Following Hematopoietic Cell Transplantation in Adult and Pediatric Patients

artículo científico publicado en 2020

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

scientific article published on 31 October 2019

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2018

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

artículo científico publicado el 10 de enero de 2011

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

artículo científico publicado en 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

artículo científico publicado en 2009

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity

artículo científico publicado en 2013

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

artículo científico publicado en 2012

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

scientific article published on 10 May 2018

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

scientific article published on 23 May 2020

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2019

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

artículo científico publicado en 2017

Ixazomib for the treatment of multiple myeloma

scientific article published on 13 November 2018

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

scientific article published on 08 May 2019

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

artículo científico publicado en 2017

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

artículo científico publicado en 2019

Kidney disease and multiple myeloma

artículo científico

Kidney disease associated with plasma cell dyscrasias

artículo científico publicado en 2010

Latest advances and current challenges in the treatment of multiple myeloma ⬇️

artículo científico publicado el 21 de febrero de 2012

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

artículo científico publicado en 2015

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

artículo científico publicado en 2017

Lenalidomide after stem-cell transplantation for multiple myeloma

artículo científico publicado en 2012

Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma

artículo científico publicado en 2014

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

artículo científico publicado en 2017

Lenalidomide in multiple myeloma

artículo científico publicado en 2006

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

artículo científico publicado el 15 de junio de 2010

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

artículo científico publicado en 2011

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2010

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

artículo científico publicado en 2011

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

scientific article published on 20 April 2020

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

artículo científico publicado el 1 de junio de 2011

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Maintenance and continuous therapy for multiple myeloma

artículo científico publicado en 2018

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 1 de octubre de 2011

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Management of myeloma-associated renal dysfunction in the era of novel therapies

artículo científico publicado en 2012

Management of relapsed and relapsed refractory myeloma

artículo científico publicado en 2007

Management of relapsed multiple myeloma after autologous stem cell transplant

artículo científico

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

artículo científico publicado el 7 de julio de 2011

Marizomib for central nervous system-multiple myeloma

artículo científico publicado en 2017

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

artículo científico publicado en 2016

Maximizing the clinical benefit of novel therapies in multiple myeloma

scientific article published on April 2009

Meaningful changes in end-of-life care among patients with myeloma

artículo científico publicado en 2018

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma ⬇️

artículo científico publicado el 1 de noviembre de 2011

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

artículo científico publicado en 2004

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

artículo científico publicado en 2017

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

scientific article published on 23 March 2020

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1

artículo científico publicado en 2021

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

artículo científico publicado en 2010

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

artículo científico publicado en 2012

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

artículo científico publicado en 2011

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

artículo científico publicado en 2012

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

artículo científico publicado en 2011

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

artículo científico publicado en 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

artículo científico publicado en 2005

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

artículo científico publicado en 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

artículo científico publicado en 2002

Monoclonal antibodies in myeloma.

artículo científico

Monoclonal antibodies in the treatment of multiple myeloma ⬇️

artículo científico publicado el 21 de julio de 2011

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

artículo científico publicado en 2002

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series

artículo científico publicado en 2015

Multiple myeloma

artículo científico publicado en 2009

Multiple myeloma

artículo científico publicado en 2004

Multiple myeloma

artículo científico publicado en 2011

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

artículo científico publicado en 2007

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

artículo científico publicado en 2013

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

artículo científico publicado en 2016

NF-kappa B as a therapeutic target in multiple myeloma

artículo científico publicado en 2002

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

artículo científico publicado en 2003

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors ⬇️

artículo científico publicado el 1 de enero de 2013

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib

artículo científico

New drugs for myeloma

artículo científico publicado en 2007

New proteasome inhibitors in myeloma

artículo científico

New treatments for multiple myeloma.

artículo científico publicado en 2005

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

artículo científico publicado en 2014

Novel biological therapies for the treatment of multiple myeloma

artículo científico publicado en 2005

Novel biologically based therapies for Waldenstrom's macroglobulinemia

artículo científico publicado en 2003

Novel biologically based therapies for multiple myeloma

artículo científico publicado en 2002

Novel targeted agents in the treatment of multiple myeloma

artículo científico

Novel therapeutic approaches for multiple myeloma

artículo científico publicado en 2003

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

artículo científico publicado en 2007

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma

artículo científico publicado en 2006

Novel therapies in myeloma

artículo científico publicado en 2007

Novel therapies in the treatment of multiple myeloma

artículo científico publicado en 2009

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

artículo científico publicado en 2007

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

artículo científico publicado en 2003

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma

artículo científico publicado en 2006

Optimizing therapy for del(17p) multiple myeloma.

artículo científico publicado en 2017

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

artículo científico publicado en 2019

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

artículo científico publicado en 2014

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma ⬇️

artículo científico publicado el 15 de agosto de 2013

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2010

Panobinostat for the Treatment of Multiple Myeloma.

artículo científico

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

artículo científico publicado en 2017

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

artículo científico

Pathological crystallization of human immunoglobulins ⬇️

artículo científico publicado el 30 de julio de 2012

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2018

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial

artículo científico publicado en 2018

Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

artículo científico publicado en 2012

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial ⬇️

artículo científico publicado el 11 de octubre de 2011

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study ⬇️

artículo científico publicado el 29 de mayo de 2012

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2006

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

artículo científico publicado en 2013

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

artículo científico publicado en 2012

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

artículo científico publicado en 2016

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib ⬇️

artículo científico publicado el 14 de diciembre de 2012

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

scientific article published on 03 March 2020

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

artículo científico publicado en 2014

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

artículo científico publicado en 2016

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

artículo científico publicado en 2016

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 30 de enero de 2012

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

artículo científico publicado en 2008

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

artículo científico publicado en 2008

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

artículo científico publicado en 2010

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

artículo científico publicado en 2010

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

artículo científico publicado en 2010

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

artículo científico publicado en 2010

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

artículo científico publicado en 2013

Phase transitions in human IgG solutions

artículo científico publicado en 2013

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

artículo científico publicado en 2014

Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile

artículo científico publicado en 2019

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

artículo científico publicado en 2016

Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma

artículo científico publicado en 2017

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

artículo científico publicado en 2020

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

scientific article published on 13 May 2019

Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

artículo científico publicado en 2020

Pomalidomide: New immunomodulatory agent with potent antiproliferative effects ⬇️

artículo científico publicado el 17 de junio de 2013

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation

artículo científico publicado en 2020

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells ⬇️

artículo científico publicado el 26 de septiembre de 2011

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

artículo científico publicado en 2009

Prediction of veno-occlusive disease using biomarkers of endothelial injury

artículo científico publicado en 2010

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients

artículo científico publicado en 2007

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy ⬇️

artículo científico publicado el 27 de octubre de 2011

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

artículo científico publicado en 2017

Promising therapies in multiple myeloma

artículo científico publicado en 2015

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group ⬇️

artículo científico publicado en 2019

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

artículo científico publicado en 2004

Proteasome inhibition as a new therapeutic principle in hematological malignancies

artículo científico publicado en 2006

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

artículo científico publicado en 2005

Proteasome inhibition in hematologic malignancies

artículo científico publicado en 2004

Proteasome inhibition in the treatment of cancer

artículo científico publicado en 2005

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

artículo científico publicado en 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

artículo científico publicado en 2002

Proteasome inhibitor therapy in multiple myeloma

artículo científico publicado en 2005

Proteasome inhibitors as therapeutics

artículo científico publicado en 2005

Proteasome inhibitors in multiple myeloma: 10 years later

artículo científico

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens

artículo científico publicado en 2015

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma

scientific article published on 10 October 2019

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

artículo científico publicado en 2017

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

artículo científico publicado en 2012

Re: When you look matters: the effect of assessment schedule on progression-free survival

artículo científico publicado en 2008

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

scientific article published on 09 March 2020

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

artículo científico publicado en 2017

Recent advances in the treatment of Multiple Myeloma

artículo científico publicado en 2006

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

artículo científico publicado en 2003

Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

artículo científico publicado en 2017

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

artículo científico publicado en 2014

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

artículo científico publicado en 2005

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia ⬇️

artículo científico publicado el 3 de enero de 2013

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

artículo científico publicado en 2014

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

artículo científico publicado en 2009

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

artículo científico publicado en 2016

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2017

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

artículo científico publicado en 2005

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

artículo científico publicado en 2010

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

artículo científico publicado en 2007

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease

artículo científico publicado en 2012

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2009

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

artículo científico publicado en 2014

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2005

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

artículo científico publicado en 2018

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition

artículo científico publicado en 2014

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

artículo científico publicado en 2019

Selinexor for the treatment of multiple myeloma

artículo científico publicado en 2020

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone ⬇️

artículo científico publicado el 27 de septiembre de 2012

Setting the standard for newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 22 de marzo de 2011

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple Myeloma

artículo científico publicado en 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

scientific article published on 05 September 2008

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

artículo científico publicado en 2005

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

artículo científico publicado en 2010

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide

artículo científico publicado en 2015

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

artículo científico publicado en 2015

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

artículo científico publicado en 2016

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

artículo científico publicado en 2010

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

artículo científico publicado en 2011

Tanespimycin as antitumor therapy.

artículo científico publicado en 2011

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

artículo científico publicado en 2008

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

artículo científico publicado en 2015

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

artículo científico publicado en 2007

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

scientific article published on 01 October 2007

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

artículo científico publicado en 2012

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

artículo científico publicado en 2006

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

artículo científico publicado en 2002

Targeting proteasome inhibition in hematologic malignancies

artículo científico publicado en 2003

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

artículo científico publicado en 2007

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

artículo científico publicado en 2007

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

artículo científico publicado en 2005

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

artículo científico publicado en 2004

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 1 de febrero de 2011

Thalidomide: emerging role in cancer medicine

artículo científico publicado en 2002

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival

artículo científico publicado en 2016

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

artículo científico publicado el 22 de noviembre de 2011

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

artículo científico publicado en 2002

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The challenge of cross-trial comparisons using limited data

artículo científico publicado en 2014

The comprehensive clinical management of multiple myeloma and related-plasma cell disorders

artículo científico publicado en 2014

The emerging role of novel therapies for the treatment of relapsed myeloma

artículo científico publicado en 2007

The evolution and impact of therapy in multiple myeloma

artículo científico publicado en 2010

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease

scientific article published on 01 August 2018

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

artículo científico publicado en 2013

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

artículo científico

The malignant clone and the bone-marrow environment

artículo científico publicado en 2007

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2009

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

artículo científico publicado el 7 de marzo de 2012

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

artículo científico publicado en 2002

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

artículo científico publicado en 2008

The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

artículo científico publicado en 2020

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

artículo científico publicado en 2007

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

artículo científico publicado en 2006

The treatment of multiple myeloma patients not eligible for asct ⬇️

artículo científico publicado el 3 de mayo de 2010

The treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2007

The use of defibrotide in blood and marrow transplantation

artículo científico publicado en 2018

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2002

Towards a better understanding of monoclonal gammopathy of renal significance

scientific article published on 28 May 2019

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

artículo científico publicado en 2004

Treatment Options for Relapsed and Refractory Multiple Myeloma ⬇️

artículo científico publicado el 15 de marzo de 2011

Treatment of Relapsed/Refractory Multiple Myeloma

artículo científico publicado en 2016

Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent

artículo científico publicado en 2017

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations

artículo científico publicado en 2018

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

artículo científico publicado en 2010

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans ⬇️

artículo científico publicado el 15 de enero de 2013

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma

artículo científico publicado en 2004

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

scientific article published on 25 June 2018

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

artículo científico publicado en 2007

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

artículo científico publicado en 2005

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

artículo científico publicado en 2016

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Use of defibrotide in the treatment and prevention of veno-occlusive disease

artículo científico publicado en 2009

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

artículo científico publicado en 2008

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

artículo científico publicado en 2004

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

artículo científico publicado en 2009

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients ⬇️

artículo científico publicado el 17 de mayo de 2013

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma ⬇️

artículo científico publicado el 28 de octubre de 2010

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment

artículo científico publicado en 2020

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

artículo científico publicado en 2003

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

artículo científico publicado en 2011

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

scientific article published on 07 March 2020

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

artículo científico publicado en 2004

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda